Literature DB >> 6610509

Prenatal diagnosis of three cases of severe combined immunodeficiency: severe T cell deficiency during the first half of gestation in fetuses with adenosine deaminase deficiency.

D C Linch, R J Levinsky, C H Rodeck, K A Maclennan, H A Simmonds.   

Abstract

The prenatal diagnosis of severe combined immunodeficiency (SCID) was made in three fetuses by staining fetal blood obtained at fetoscopy with a panel of monoclonal antibodies. There were less than 100 T cells/mm3 of fetal blood in these three cases compared to 2,500/mm3 in 14 immunologically normal fetuses. Cells bearing the cortical thymocyte antigen (NA1/34) were not detected in any of the normal or affected fetal blood samples. Two of the affected fetuses were also homozygous for a deficiency of adenosine deaminase (ADA) with undetectable levels of red cell ADA. All three affected fetuses were aborted and postmortem tissue was obtained in two cases. In both of these cases the thymus was markedly hypoplastic and contained no lymphoid cells. One of these fetuses was homozygous for ADA deficiency and the virtual absence of T cells or thymocytes during the second trimester of pregnancy indicates that placental access to the maternal circulation does not prevent damage to the T lineage stem cells in this disease. Prenatal diagnosis of SCID has previously only been possible in patients with a defined metabolic defect such as ADA deficiency, but these studies indicate that prenatal diagnosis now may be offered for most at risk pregnancies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6610509      PMCID: PMC1536238     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

Review 1.  Monoclonal antibodies for analysis of the HLA system.

Authors:  F M Brodsky; P Parham; C J Barnstable; M J Crumpton; W F Bodmer
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

2.  Comparison of the direct antiglobulin rosetting reaction with the mixed antiglobulin rosetting reaction for the detection of immunoglobulin on lymphocytes.

Authors:  R R Coombs; A B Wilson; O Eremin; B W Gurner; D G Haegert; Y A Lawson; S Bright; A J Munro
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

3.  An improved rosetting assay for detection of human T lymphocytes.

Authors:  M E Kaplan; C Clark
Journal:  J Immunol Methods       Date:  1974-07       Impact factor: 2.303

4.  Histopathological findings in the combined immunity-deficiency syndrome.

Authors:  C L Berry
Journal:  J Clin Pathol       Date:  1970-04       Impact factor: 3.411

5.  Ontogeny of human T cells.

Authors:  D P Stites; C S Pavia
Journal:  Pediatrics       Date:  1979-11       Impact factor: 7.124

Review 6.  The differentiation and function of human T lymphocytes.

Authors:  E L Reinherz; S F Schlossman
Journal:  Cell       Date:  1980-04       Impact factor: 41.582

7.  Fetoscopy guided by real-time ultrasound for pure fetal blood samples, fetal skin samples, and examination of the fetus in utero.

Authors:  C H Rodeck
Journal:  Br J Obstet Gynaecol       Date:  1980-06

Review 8.  Enzyme replacement and other biochemical approaches to the therapy of adenosine deaminase deficiency.

Authors:  S H Polmar
Journal:  Ciba Found Symp       Date:  1978

9.  A human thymocyte antigen defined by a hybrid myeloma monoclonal antibody.

Authors:  A J McMichael; J R Pilch; G Galfré; D Y Mason; J W Fabre; C Milstein
Journal:  Eur J Immunol       Date:  1979-03       Impact factor: 5.532

10.  Adenosine-deaminase deficiency in a child diagnosed prenatally.

Authors:  R Hirschhorn; N Beratis; F S Rosen; R Parkman; R Stern; S Polmar
Journal:  Lancet       Date:  1975-01-11       Impact factor: 79.321

View more
  8 in total

1.  Fetal tissue sampling. The San Francisco experience with 190 pregnancies.

Authors:  M S Golbus; K F McGonigle; J D Goldberg; R A Filly; P W Callen; R L Anderson
Journal:  West J Med       Date:  1989-04

2.  Early prenatal investigation of a pregnancy at risk of adenosine deaminase deficiency using chorionic villi.

Authors:  D A Aitken; D H Gilmore; C A Frew; M E Ferguson-Smith; M J Carty; W R Chatfield
Journal:  J Med Genet       Date:  1986-02       Impact factor: 6.318

3.  Pathologic findings in adenosine deaminase deficient-severe combined immunodeficiency. II. Thymus, spleen, lymph node, and gastrointestinal tract lymphoid tissue alterations.

Authors:  H Ratech; R Hirschhorn; M A Greco
Journal:  Am J Pathol       Date:  1989-12       Impact factor: 4.307

4.  Serum IgG subclasses and IgM imbalances in adult IgA mesangial glomerulonephritis and idiopathic Henoch-Schoenlein purpura.

Authors:  G Rostoker; M A Pech; S Del Prato; M Petit-Phar; A Ben Maadi; J M Dubert; P Lang; B Weil; G Lagrue
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

5.  Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations.

Authors:  H Ratech; M A Greco; G Gallo; D L Rimoin; H Kamino; R Hirschhorn
Journal:  Am J Pathol       Date:  1985-07       Impact factor: 4.307

6.  Insulin-dependent diabetes mellitus and severe atopic dermatitis in a child with adenosine deaminase deficiency.

Authors:  L D Notarangelo; G Stoppoloni; R Toraldo; E Mazzolari; A Coletta; P Airò; C Bordignon; A G Ugazio
Journal:  Eur J Pediatr       Date:  1992-11       Impact factor: 3.183

7.  Restoration of adenosine deaminase-deficient human thymocyte development in vitro by inhibition of deoxynucleoside kinases.

Authors:  Michelle L Joachims; Patrick A Marble; Aletha B Laurent; Peter Pastuszko; Marco Paliotta; Michael R Blackburn; Linda F Thompson
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

8.  Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice.

Authors:  M Wakamiya; M R Blackburn; R Jurecic; M J McArthur; R S Geske; J Cartwright; K Mitani; S Vaishnav; J W Belmont; R E Kellems
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.